Biochemical activities of the derivatives of dehydrodicaffeic acid dilactone.
Activities of derivatives of dehydrodicaffeic acid dilactone (DDCAD) to inhibit catechol-O-methyltransferase (COMT), cyclic AMP phosphodiesterase (PDE) and DOPA decarboxylase (DDC) were examined. Among those tested, 2,6-bis-(5',6'-dibromo-4'-hydroxy-3'-methoxyphenyl)-3,7-dioxabicyclo-[3,3,0]-octane 4,8-dione was found to be the strongest inhibitor of both COMT and PDE. There were no derivatives which showed a stronger inhibition against DDC than the original compound, DDCAD.
D015105:3',5'-Cyclic-AMP Phosphodiesterases / Q000037:antagonists & inhibitors*; D000818:Animals; D065105:Aromatic Amino Acid Decarboxylase Inhibitors; D002109:Caffeic Acids / Q000494:pharmacology*; D065098:Catechol O-Methyltransferase Inhibitors; D002934:Cinnamates / Q000494:pharmacology*; D066298:In Vitro Techniques; D007700:Kinetics; D007783:Lactones / Q000494:pharmacology; D008274:Magnesium / Q000494:pharmacology; D051379:Mice; D013329:Structure-Activity Relationship
D065105:Aromatic Amino Acid Decarboxylase Inhibitors; D002109:Caffeic Acids; D065098:Catechol O-Methyltransferase Inhibitors; D002934:Cinnamates; D007783:Lactones; D015105:3',5'-Cyclic-AMP Phosphodiesterases; D008274:Magnesium